Duncan Armour

1.9k total citations · 1 hit paper
14 papers, 1.5k citations indexed

About

Duncan Armour is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Infectious Diseases. According to data from OpenAlex, Duncan Armour has authored 14 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 5 papers in Cellular and Molecular Neuroscience and 3 papers in Infectious Diseases. Recurrent topics in Duncan Armour's work include Receptor Mechanisms and Signaling (5 papers), Neuropeptides and Animal Physiology (5 papers) and HIV Research and Treatment (3 papers). Duncan Armour is often cited by papers focused on Receptor Mechanisms and Signaling (5 papers), Neuropeptides and Animal Physiology (5 papers) and HIV Research and Treatment (3 papers). Duncan Armour collaborates with scholars based in United Kingdom and United States. Duncan Armour's co-authors include Anthony Wood, Blanda Stammen, Manos Perros, Carolyn Napier, David A. Price, Julie Mori, Malcolm Macartney, Paul Griffin, Rob Webster and Patrick Dorr and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Medicinal Chemistry and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Duncan Armour

14 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

2005 909 citations Patrick Dorr, Mike Westby et al. Antimicrobial Agents and Chemotherapy profile →

Peers

Countries citing papers authored by Duncan Armour

Since Specialization

Citations

This map shows the geographic impact of Duncan Armour's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Duncan Armour with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Duncan Armour more than expected).

Fields of papers citing papers by Duncan Armour

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Duncan Armour. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Duncan Armour. The network helps show where Duncan Armour may publish in the future.

Co-authorship network of co-authors of Duncan Armour

This figure shows the co-authorship network connecting the top 25 collaborators of Duncan Armour. A scholar is included among the top collaborators of Duncan Armour based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Duncan Armour. Duncan Armour is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Overcoming hERG Affinity in the Discovery of Maraviroc; A CCR5 Antagonist for the Treatment of HIV 2008 ·Current Topics in Medicinal Chemistry ·David A. Price, Duncan Armour, Marcel de Groot, Derek J. Leishman, Carolyn Napier, Manos Perros, Blanda Stammen, Anthony Wood	11
2	The Discovery of CCR5 Receptor Antagonists for the Treatment of HIV Infection: Hit‐to‐Lead Studies 2006 ·ChemMedChem ·Duncan Armour, Marcel J. de Groot, Martin P. Edwards, Manos Perros, David A. Price, Blanda Stammen, Anthony Wood	17
3	Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc 2006 ·Bioorganic & Medicinal Chemistry Letters ·David A. Price, Duncan Armour, Marcel de Groot, Derek J. Leishman, Carolyn Napier, Manos Perros, Blanda Stammen, Anthony Wood	49
4	Synthesis and applications of tert-alkoxysiloxane linkers in solid-phase chemistry 2006 ·Tetrahedron ·Marco Meloní, (unknown), Duncan Armour, Richard C. D. Brown	7
5	The Discovery of the CCR5 Receptor Antagonist, UK-427,857, A New Agent for the Treatment of HIV Infection and AIDS 2005 ·Progress in medicinal chemistry ·Anthony Wood, Duncan Armour	117
6	Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity breakdown → 2005 ·Antimicrobial Agents and Chemotherapy ·Patrick Dorr, Mike Westby, (unknown), Paul Griffin, (unknown), Malcolm Macartney, Julie Mori, (unknown), Caroline Smith‐Burchnell, Carolyn Napier, Rob Webster, Duncan Armour, David A. Price, Blanda Stammen, Anthony Wood, Manos Perros	909
7	Novel silyl linkers for solid-phase synthesis 2002 ·Tetrahedron Letters ·Marco Meloní, Richard C. D. Brown, Peter D. White, Duncan Armour	7
8	Enantioselective Synthesis of 3,6-Dihydro-1H-pyridin-2-ones: Unexpected Regioselectivity in the Palladium-Catalyzed Decarboxylative Carbonylation of 5-Vinyloxazolidin-2-ones 2000 ·Journal of the American Chemical Society ·Julian G. Knight, (unknown), (unknown), Simon J. Harwood, (unknown), Duncan Armour, David M. Hollinshead, Albert Jaxa‐Chamiec	56
9	1,4-Benzodiazepin-2-one derived neurokinin-1 receptor antagonists 1997 ·Bioorganic & Medicinal Chemistry Letters ·Duncan Armour, (unknown), (unknown), Miles Congreve, A.B. Hawcock, Daniel G. Marquess, J.E. Mordaunt, (unknown), P. Ward	9
10	GR205171: A novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity 1996 ·Regulatory Peptides ·C. Gardner, Duncan Armour, David T. Beattie, Jeremy D. Gale, A.B. Hawcock, Gavin J. Kilpatrick, D.J. Twissell, P. Ward	122
11	Tetrazole NK1 receptor antagonists: The identification of an exceptionally potent orally active antiemetic compound 1996 ·Bioorganic & Medicinal Chemistry Letters ·Duncan Armour, Kyeongwoon Chung, Miles Congreve, Brian Evans, Stephen B. Guntrip, Thomas Hubbard, (unknown), David Middlemiss, J.E. Mordaunt, Neil Pegg, V. Vinader, P. Ward, (unknown)	34
12	Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity. 1. Optimization of the Agonist “Trigger” 1996 ·Journal of Medicinal Chemistry ·Christopher Aquino, Duncan Armour, Judd Berman, Larry S. Birkemo, Robin A. E. Carr, Dallas K. Croom, Milana Dezube, R. W. Dougherty, Gregory N. Ervin, Mary K. Grizzle, (unknown), Gavin C. Hirst, Michael K. James, Michael F. Johnson, Laurence J. Miller, Kennedy L. Queen, Thomas J. Rimele, David Norman Smith, Elizabeth E. Sugg	79
13	Discovery of an Orally Bioavailable NK1 Receptor Antagonist, (2S,3S)-(2-Methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR203040), with Potent Antiemetic Activity 1995 ·Journal of Medicinal Chemistry ·P. Ward, Duncan Armour, (unknown), Brian Evans, Gerard M.P. Giblin, Nicola M. Heron, (unknown), Kai Liang, David Middlemiss	41
14	Spiro-piperidine non-peptide neurokinin-1 receptor antagonists 1995 ·Bioorganic & Medicinal Chemistry Letters ·Duncan Armour, (unknown), Neil Pegg, Nicola M. Heron, David Middlemiss, (unknown), (unknown), Thomas Hubbard, V. Vinader, (unknown), (unknown), (unknown), P. Ward	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact